MUMBAI, India — Glenmark Pharmaceuticals Inc. USA has received final approval from the Food and Drug Administration for lidocaine ointment 5%.
Glemark said its product is a generic version of Xylocaine ointment 5% from AstraZeneca.
A local anesthetic, lidocaine ointment is used for the treatment of pain or discomfort from skin irritations such as sunburn; insect bites; poison ivy, oak and sumac; and minor cuts, scratches and burns.
For the 12 months ended in July, branded and generic Xylocaine ointment 5% totaled sales of approximately $373.0 million, according to IMS Health data reported by Glenmark.
